P

Pedestal Health

Sponsors real-world evidence for drug development

Head of Technology

Full-TimePosted on 10/19/2026
No salary listed
Expert
Research Triangle Park, Durham, NC, USA
HybridThree days per week in the office are required.
Engineering ManagementEngineering Leadership

About the job

Requirements
  • At least 12 years of engineering experience, including at least 5 years leading multi-team organizations through engineering managers.
  • Experience working with healthcare organizations and healthcare data.
  • Experience overseeing corporate IT, directly or through an IT leader.
  • Deep technical grounding in AWS data architecture, including S3, Glue, Athena, EMR, Lake Formation, and IAM, and infrastructure as code sufficient to set direction and pressure-test designs.
  • Experience with a cloud data warehouse such as Snowflake.
  • Working knowledge of HIPAA and security frameworks such as HITRUST or SOC 2.
  • A track record of hiring and developing engineering leaders and scaling teams and platforms from early stage to growth.
  • Experience owning an engineering budget, including cloud spend and vendor contracts.
  • Clear written and verbal communication and sound judgment in balancing speed, cost, and rigor.
Responsibilities
  • Set the strategy and architecture for acquiring clinical data from health system partners across Epic, Cerner, and other electronic health record systems.
  • Own the approach to de-identification and tokenization, balancing accuracy, speed, cost, and privacy, including the associated vendor partnerships.
  • Set standards for data reliability, completeness, and quality, and make quality measurable and visible with Quantitative Sciences.
  • Ensure datasets meet business associate agreement and data use agreement commitments, from retention through destruction.
  • Shape the data expansion roadmap with Product and Commercial, including claims linkage and new third-party sources.
  • Own the technology vision for the data platform and products built on it.
  • Make major architecture and build-versus-buy decisions, and set engineering standards.
  • Ensure the platform scales to meet demand from artificial intelligence and machine learning, Quantitative Sciences, and Product.
  • Be accountable for cloud cost efficiency as data volume and partner sites grow.
  • Own the company's security and compliance posture, including HIPAA, HITRUST, and SOC 2, and report risk to leadership.
  • Serve as the accountable executive in health system and sponsor security reviews and audits.
  • Set enterprise IT strategy through the IT leader to provide secure, reliable tools that scale with the company.
  • Partner with the Head of AI/ML to make AI governance enforceable through technical controls.
  • Lead and develop engineering and IT leaders, holding them accountable for delivery, quality, and team health.
  • Design the engineering and IT organization as it grows, including team structure, hiring plans, career paths, and decisions on building, buying, or outsourcing.
  • Set the operating rhythm, including planning, delivery metrics, on-call practices, and incident review.
  • Own the engineering and IT budget, including cloud spend and vendor contracts.
  • Serve as the executive counterpart to health system IT leaders during partner onboarding.
  • Partner with Product, Quantitative Sciences, Medical, Commercial, and Clinical Operations on roadmap and priorities.
  • Translate technical tradeoffs into clear business terms for the leadership team.
Desired Qualifications
  • Experience supporting machine learning and large language model workloads in production.
  • Familiarity with FHIR, OMOP, or other clinical data standards.
  • Experience with tokenization and privacy-preserving record linkage, such as Datavant.

About the company

Pedestal Health focuses on real-world evidence (RWE) by designing and sponsoring disease-specific patient cohorts to generate regulatory-grade data and insights for drug development. It builds customizable RWE communities that provide researchers with high-quality data, enabling regulatory submissions and informed decision-making for pharmaceutical companies, regulators, and healthcare providers. The company offers tailored data solutions, consulting services, and biospecimen samples, funded through partnerships and service contracts. Its main differentiator is assembling end-to-end, disease-focused RWE networks and supplying both data and biological materials, rather than just aggregating datasets. The goal is to help clients accelerate and improve drug development and regulatory processes by delivering robust, real-world insights grounded in well-characterized patient cohorts.

Company Size

51-200

Company Stage

Seed

Total Funding

$2.8M

Headquarters

Durham, North Carolina

Founded

2015

Get referred to Pedestal Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 2026 leadership hires in commercial, delivery, and finance support scaling.
  • 2026 publications for Merck, Amgen, and AbbVie validate commercial demand.
  • Rebrand on May 18, 2026 signals broader positioning beyond Target RWE's legacy brand.

What critics are saying

  • Narrow disease focus makes MASH, PBC, PSC, and IBD pipeline concentration severe.
  • Competing CROs and data vendors can replicate single-disease evidence services by 2027.
  • If major pharma programs shift to internal RWE teams, Pedestal Health loses core revenue.

What makes Pedestal Health unique

  • Pedestal Health built decade-long longitudinal cohorts in hepatology, dermatology, and gastroenterology.
  • Its hybrid model combines EHR, prospective collection, biomarkers, imaging, and external controls.
  • Highlander Health acquired Target RWE in January 2025, backing regulatory-grade evidence generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options
  • Comprehensive health, dental, and vision for you and your family
  • 401(k) with company match
  • Generous PTO and company holidays
  • Paid parental leave

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

1%

2 year growth

0%
Business Wire
Apr 2nd, 2026
Target RWE appoints leadership across delivery, finance and commercial to scale evidence generation operations

Target RWE, a clinical evidence generation company, has announced three senior leadership appointments to support its growth. Steve Swanson has been promoted to chief commercial officer, leading commercial strategy and partnerships with biopharma and healthcare companies. Emily Akin joins as head of delivery, overseeing clinical operations and data curation. She previously led Flatiron Trials and Research Network at Flatiron Health. Ashley Pierce has been appointed head of finance, bringing experience from Syneos Health and Capitol Broadcasting Company. The company, backed by investment firm Highlander Health, specialises in real-world evidence generation designed to meet regulatory standards for drug development. The leadership team collectively brings nearly 70 years of experience across life sciences and healthcare to advance Target RWE's evidence generation and clinical trial capabilities.

Business Wire
Nov 6th, 2025
Target RWE Announces Upcoming Presentations at AASLD - The Liver Meeting 2025

Target RWE announces upcoming presentations at AASLD - The Liver Meeting 2025. DURHAM, N.C.-(BUSINESS WIRE)-Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced it will have multiple presentations focused on the testing and related outcomes of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(R) 2025, taking place November 7-11, 2025 in Washington, D.C. Poster Number: 2114 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Changes in the Fibrosis-4 (FIB-4) score accurately reflects the disease trajectory of metabolic dysfunction associated steatotic liver disease. Presenter: Vinay Jahagirdar, MD, GI Fellow, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia. Summary: A FIB-4 score of 1.3-2.6 reflects an intermediate risk stratum of MASLD where secondary tests with vibration-controlled transient elastography (VCTE) repeat testing is recommended. VCTE is not, however, universally available and the utility of repeat FIB-4 testing to assess changes in clinical status in MASLD is not known. The study authors hypothesized that changes in FIB-4 will coordinately track the risk of clinical outcomes in MASLD. The aim of this study was to define the performance of changes in FIB-4 as a disease-monitoring test in MASLD. The authors concluded that changes in FIB-4 predict future risk of adverse health outcomes independent of age and changes in BMI. Thus, in this intermediate risk FIB-4 category especially with T2DM, repeat testing and change in FIB-4 can be used to assess prognosis and disease trajectory. Poster Number: 2618 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Clinical characteristics and outcomes of patients with presumed MASLD who meet MetALD criteria in the TARGET-NASH cohort Presenter: A. Sidney Barritt IV, MD, MSCR, Professor of Medicine, Director of Hepatology, and Transplant Hepatology Program Director in the Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill. Summary: Many patients with hepatic steatosis are presumed to have MASLD due to comorbid cardiovascular (CV) risk factors. However, alcohol use may not be accurately quantified by providers or fully disclosed by some patients. The characteristics and outcomes of patients with MASLD and increased alcohol intake - metabolic dysfunction and alcohol-related liver disease (MetALD) - are unknown. The study sought to describe these patients in the TARGET-NASH cohort and found that despite younger age and fewer metabolic risk factors, MetALD patients suffered a similar number of incident, major adverse cardiovascular(MACE) events on a faster timeframe compared with traditional MASLD patients. About Target RWE Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy. Visit our website to learn more: https://targetrwe.com/

Newswise
May 9th, 2025
Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research

Target RWE unveiled findings on MASH and HCC and contributed expert leadership to the highly anticipated PBC Consensus Conference on May 6th.

PR Newswire
Mar 7th, 2025
Patient-Centric Data Capture Fuels Growth Of Target Rwe Longitudinal, Real-World Dermatology Studies

Insights into Hidradenitis Suppurativa from Target RWE Featured in Posters at AAD 2025 DURHAM, N.C., March 7, 2025 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster presentations on patients with Hidradenitis Suppurativa (HS) at the American Academy of Dermatology (AAD) annual meeting in Orlando, FL, March 7-11, 2025

Business Wire
Jan 8th, 2025
Highlander Health Announces Inaugural Investment of Target RWE

Highlander Health today announced the acquisition of Target RWE from existing investors, including 22C Capital.